Sharma Meena R, Koltowski Lauren, Ownbey Robert T, Tuszynski George P, Sharma Mahesh C
University of Pennsylvania, Philadelphia, PA 19104, USA.
Exp Mol Pathol. 2006 Oct;81(2):146-56. doi: 10.1016/j.yexmp.2006.03.003. Epub 2006 Apr 27.
Many advanced human tumors including breast cancer overproduce plasmin that is known to promote angiogenesis and metastasis. The mechanism of this effect is poorly understood. Here we report that annexin II, an endothelial co-receptor for tPA (tissue-type plasminogen activator) and plasminogen, was undetectable in normal and hyperplastic ductal epithelial cells and ductal complexes. By contrast, it was consistently expressed in invasive breast cancer and ductal carcinoma in situ (DCIS) indicating its involvement in breast cancer. Using the well established invasive/metastatic MDA-MB231 cell line and the noninvasive/nonmetastatic MCF-7 human breast cancer cell line, we investigated the mechanism by which annexin II regulates breast cancer progression and metastasis. Western and Northern blot analyses demonstrate selective expression of annexin II in MDA-MB231 cells but not in poorly invasive MCF-7 cells suggesting its participation in invasive breast cancer. Since annexin II is a receptor for plasminogen, we tested whether MDA-MB231 cells are capable of producing plasmin in vitro. MDA-MB231 cell membranes induced plasmin generation in a time-dependent manner while those from MCF-7 cells failed to convert plasminogen to plasmin. The generated plasmin is capable of degrading ECM consequently facilitating cell invasion and migration, biological functions required for angiogenesis and metastasis. Plasmin generation and its dependent invasion and migration can be blocked by a monoclonal antibody to annexin II or angiostatin, potent inhibitors of angiogenesis, breast cancer, and metastasis. Our findings indicate that annexin II-dependent localized plasmin generation by human breast cancer cells could contribute to angiogenesis and metastasis. These results suggest that annexin II may be an attractive target for new anti-angiogenic and anti-breast cancer therapies.
包括乳腺癌在内的许多晚期人类肿瘤都会过度产生纤溶酶,已知纤溶酶会促进血管生成和转移。这种效应的机制尚不清楚。在此,我们报告膜联蛋白II,一种组织型纤溶酶原激活剂(tPA)和纤溶酶原的内皮细胞共受体,在正常和增生性导管上皮细胞及导管复合体中无法检测到。相比之下,它在浸润性乳腺癌和原位导管癌(DCIS)中持续表达,表明其参与了乳腺癌的发生。利用成熟的具有侵袭性/转移性的MDA-MB231细胞系和无侵袭性/无转移性的MCF-7人乳腺癌细胞系,我们研究了膜联蛋白II调节乳腺癌进展和转移的机制。蛋白质免疫印迹法(Western blot)和Northern印迹法分析表明,膜联蛋白II在MDA-MB231细胞中选择性表达,而在侵袭性较差的MCF-7细胞中不表达,提示其参与了浸润性乳腺癌的发生。由于膜联蛋白II是纤溶酶原的受体,我们测试了MDA-MB231细胞在体外是否能够产生纤溶酶。MDA-MB231细胞膜以时间依赖性方式诱导纤溶酶生成,而MCF-7细胞的细胞膜则无法将纤溶酶原转化为纤溶酶。生成的纤溶酶能够降解细胞外基质(ECM),从而促进细胞侵袭和迁移,这是血管生成和转移所需的生物学功能。纤溶酶的生成及其依赖性侵袭和迁移可被抗膜联蛋白II单克隆抗体或血管抑素(一种血管生成、乳腺癌和转移的有效抑制剂)阻断。我们的研究结果表明,人乳腺癌细胞依赖膜联蛋白II的局部纤溶酶生成可能有助于血管生成和转移。这些结果表明,膜联蛋白II可能是新型抗血管生成和抗乳腺癌治疗的一个有吸引力的靶点。